Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended September 30, 2014. The filing compares the three months ended September 30, 2014 with the same period in 2013; balance-sheet figures are compared with June 30, 2014.
Business context
Palatin is a development-stage biopharmaceutical company focused on peptide therapeutics. Its lead program is bremelanotide for female sexual dysfunction (FSD); other programs include PL-3994 and melanocortin receptor candidates. The company has no products available for commercial sale and depends on collaborations and external financing to fund development.
Financial results and liquidity
| Metric | Three months ended Sep. 30, 2014 | Three months ended Sep. 30, 2013 |
|---|---|---|
| Revenue | $4.93 million | $0 |
| Research and development expense | $2.92 million | $3.45 million |
| General and administrative expense | $1.11 million | $1.04 million |
| Operating income (loss) | $0.89 million | $(4.49) million |
| Net income (loss) | $0.79 million | $(4.49) million |
| Net income (loss) per common share, basic and diluted | $0.01 | $(0.04) |
| Cash provided by (used in) operating activities | $5.73 million | $(2.05) million |
The 2014 revenue was license revenue from the Gedeon Richter agreement, not product sales. It produced reported operating and net income for the quarter; operating and net margins were approximately 18% and 16%, respectively. The filing does not report a separate gross margin.
Cash and cash equivalents were $17.79 million at September 30, up from $12.18 million at June 30. Operating cash flow benefited principally from the Richter upfront payment and a $3.93 million increase in deferred revenue. Current liabilities were $7.65 million, including $4.93 million of deferred revenue; excluding deferred revenue, they were approximately $2.72 million. Total liabilities were $7.65 million, with no debt balance reported. Accumulated deficit was $273.24 million.
Cash used in financing activities was $0.12 million, primarily employee tax withholding on vested restricted stock units; there were no investing cash flows. A $0.10 million foreign-exchange transaction loss reduced other income.
Material changes and agreements
- Compared with the prior-year quarter, revenue increased from zero following the August 2014 definitive license, co-development and commercialization agreement with Gedeon Richter for bremelanotide in Europe and selected countries. Palatin recorded $4.93 million as revenue and $4.93 million as deferred revenue from the upfront consideration.
- R&D expense declined about 15% year over year, while G&A expense increased about 7%.
- The Richter agreement provides a $3.2 million milestone upon initiation of Palatin’s U.S. Phase 3 program, potential additional regulatory and sales milestones of up to approximately $101.2 million, and low double-digit royalties on licensed-territory net sales. Richter shares European development costs and is responsible for commercial activities there. If Palatin does not initiate Phase 3 by December 31, 2014, Richter may terminate and seek repayment of half of the upfront payments.
- All quarterly revenue came from Richter. The AstraZeneca collaboration could provide future milestones and royalties, but AstraZeneca was evaluating its program; the filing notes it discontinued AZD2820 development following a serious adverse event.
Outlook, risks and unusual items
- Management planned to begin patient enrollment in bremelanotide Phase 3 in calendar Q4 2014, but said it could delay or curtail initiation without adequate funding or commitments to complete the trials. The estimated Phase 3 program and related regulatory filings will cost at least $80 million.
- Management believed existing resources would fund planned operations through the quarter ending December 31, 2015, excluding initiation of the pivotal Phase 3 program and other planned clinical trials. The company expects significant losses for fiscal 2015 and additional losses for at least the next few years.
- Palatin intended to seek additional capital through partnerships, equity or debt financings, or other sources. Financing may be unavailable on acceptable terms and could dilute shareholders, restrict operations, or require the company to surrender rights.
- Key risks include clinical-trial and regulatory uncertainty, the need for substantial financing, reliance on third-party researchers and manufacturers, uncertain market acceptance and reimbursement, and dependence on collaboration partners. The company also disclosed potential dilution from outstanding warrants, options, preferred stock and restricted stock units.
- The quarter’s profit and positive operating cash flow were materially driven by the Richter license payment and associated deferred revenue; they should not be taken as evidence of recurring product revenue or sustained profitability.
- The controls discussion says management concluded controls were effective “as of September 30, 2013,” although this is the quarter ended September 30, 2014. The filing text does not clarify whether this is a typographical error.
Important facts for investors to verify
- Whether Phase 3 enrollment began on schedule, whether adequate funding was secured, and how the at-least-$80 million program would be financed.
- The status of the Richter agreement, including the December 31, 2014 initiation condition, any repayment or termination rights, and the recognition and collectability of deferred revenue and future milestones.
- Whether reported quarterly income and cash generation recur; the period’s revenue was entirely collaboration-related and from one partner.
- The status of AstraZeneca’s melanocortin program following the AZD2820 discontinuation and its implications for potential collaboration value.
- The share-count and dilution implications of the filing’s weighted-average EPS denominator (106.95 million basic shares) versus 39.49 million issued common shares at September 30, including the large outstanding warrant balance.
- The apparent September 30, 2013 date in the controls disclosure and the company’s actual quarter-end assessment.